LifeSci Capital analyst Patrick Dolezal maintained a Buy rating on Ibio today and set a price target of $5.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Patrick Dolezal has given his Buy rating due to a combination of factors related to IBIO-600’s clinical and mechanistic profile. He highlights that IBIO-600’s long half-life and robust myostatin inhibition in obese non-human primates translated into meaningful reductions in fat mass and gains in lean mass, suggesting differentiated potential in obesity treatment, especially alongside incretin drugs to preserve muscle.
He also emphasizes that IBIO-600 serves as an important validation point for iBio’s broader antibody engineering platform, with potential read-through to other assets such as IBIO-610 and the myostatin x activin A bispecific candidate. The shared half-life extension technology across these programs could translate into infrequent dosing in humans, expanding commercial appeal, while the company’s current cash runway supports advancing these assets through key early milestones, collectively underpinning his positive stance on the stock.
According to TipRanks, Dolezal is a 5-star analyst with an average return of 15.9% and a 44.32% success rate. Dolezal covers the Healthcare sector, focusing on stocks such as Ibio, Kodiak Sciences, and Neurogene.